Tags

Type your tag names separated by a space and hit enter

Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.
Cancer Epidemiol Biomarkers Prev. 1999 May; 8(5):413-9.CE

Abstract

This study was undertaken to explore whether the incidence of breast tumors that overexpress HER-2/neu protein product (HER-2/neu+) is more strongly associated with oral contraceptives (OCs) and other factors than is the incidence of tumors that do not (HER-2/neu-). In a population-based sample of women <45 years, 42.9% (159 of 371) of in situ and invasive breast cancer cases were HER-2/neu+ as assessed by immunohistochemistry in archived tissue. Polytomous logistic regression was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for HER-2/neu+ and HER-2/neu-breast cancer, as compared with 462 population-based controls, in relation to OCs and other factors. The ratio of the ORs (HER-2/neu+ versus HER-2/neu-tumors) was used as an indicator of heterogeneity in risk. There was little heterogeneity in risk for OC use of 6 months or more by HER-2/neu status (age-adjusted ratio of ORs, 1.29; 95% CI, 0.83-2.00). Among early pill users (< or =18 years of age) heterogeneity was apparent (2.39; 95% CI, 1.08-5.30), which was attenuated in a multivariate model (1.99; 95% CI, 0.87-4.54); among cases with estrogen receptor-negative tumors, heterogeneity increased to 5-fold. For other risk factors, there was no marked heterogeneity between + and - tumors for HER-2/neu. In summary, the incidence of breast cancer among younger women in relation to OC use at an early age varied with HER-2/neu status, with the odds ratio for +tumors twice that for -tumors.

Authors+Show Affiliations

Columbia University, Joseph L. Mailman School of Public Health, Division of Epidemiology, New York, New York 10032, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

10350436

Citation

Gammon, M D., et al. "Oral Contraceptive Use and Other Risk Factors in Relation to HER-2/neu Overexpression in Breast Cancer Among Young Women." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 8, no. 5, 1999, pp. 413-9.
Gammon MD, Hibshoosh H, Terry MB, et al. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev. 1999;8(5):413-9.
Gammon, M. D., Hibshoosh, H., Terry, M. B., Bose, S., Schoenberg, J. B., Brinton, L. A., Bernstein, J. L., & Thompson, W. D. (1999). Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 8(5), 413-9.
Gammon MD, et al. Oral Contraceptive Use and Other Risk Factors in Relation to HER-2/neu Overexpression in Breast Cancer Among Young Women. Cancer Epidemiol Biomarkers Prev. 1999;8(5):413-9. PubMed PMID: 10350436.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. AU - Gammon,M D, AU - Hibshoosh,H, AU - Terry,M B, AU - Bose,S, AU - Schoenberg,J B, AU - Brinton,L A, AU - Bernstein,J L, AU - Thompson,W D, PY - 1999/6/1/pubmed PY - 1999/6/1/medline PY - 1999/6/1/entrez KW - Americas KW - Biology KW - Breast Cancer KW - Cancer KW - Case Control Studies KW - Contraception KW - Contraceptive Methods KW - Developed Countries KW - Diseases KW - Examinations And Diagnoses KW - Family Planning KW - Incidence KW - Laboratory Examinations And Diagnoses KW - Laboratory Procedures KW - Measurement KW - Neoplasms KW - New Jersey KW - North America KW - Northern America KW - Oral Contraceptives KW - Research Methodology KW - Research Report KW - Risk Factors KW - Studies KW - United States SP - 413 EP - 9 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 8 IS - 5 N2 - This study was undertaken to explore whether the incidence of breast tumors that overexpress HER-2/neu protein product (HER-2/neu+) is more strongly associated with oral contraceptives (OCs) and other factors than is the incidence of tumors that do not (HER-2/neu-). In a population-based sample of women <45 years, 42.9% (159 of 371) of in situ and invasive breast cancer cases were HER-2/neu+ as assessed by immunohistochemistry in archived tissue. Polytomous logistic regression was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for HER-2/neu+ and HER-2/neu-breast cancer, as compared with 462 population-based controls, in relation to OCs and other factors. The ratio of the ORs (HER-2/neu+ versus HER-2/neu-tumors) was used as an indicator of heterogeneity in risk. There was little heterogeneity in risk for OC use of 6 months or more by HER-2/neu status (age-adjusted ratio of ORs, 1.29; 95% CI, 0.83-2.00). Among early pill users (< or =18 years of age) heterogeneity was apparent (2.39; 95% CI, 1.08-5.30), which was attenuated in a multivariate model (1.99; 95% CI, 0.87-4.54); among cases with estrogen receptor-negative tumors, heterogeneity increased to 5-fold. For other risk factors, there was no marked heterogeneity between + and - tumors for HER-2/neu. In summary, the incidence of breast cancer among younger women in relation to OC use at an early age varied with HER-2/neu status, with the odds ratio for +tumors twice that for -tumors. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/10350436/Oral_contraceptive_use_and_other_risk_factors_in_relation_to_HER_2/neu_overexpression_in_breast_cancer_among_young_women_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=10350436 DB - PRIME DP - Unbound Medicine ER -